These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 28624548)
1. Glucocorticoids and gut bacteria: "The GALF Hypothesis" in the metagenomic era. Morris DJ; Ridlon JM Steroids; 2017 Sep; 125():1-13. PubMed ID: 28624548 [TBL] [Abstract][Full Text] [Related]
2. Modulation of 11β-hydroxysteroid dehydrogenase functions by the cloud of endogenous metabolites in a local microenvironment: The glycyrrhetinic acid-like factor (GALF) hypothesis. Morris DJ; Brem AS; Odermatt A J Steroid Biochem Mol Biol; 2021 Nov; 214():105988. PubMed ID: 34464733 [TBL] [Abstract][Full Text] [Related]
3. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol. Morris DJ; Latif SA; Hardy MP; Brem AS J Steroid Biochem Mol Biol; 2007 May; 104(3-5):161-8. PubMed ID: 17459698 [TBL] [Abstract][Full Text] [Related]
4. Role of gut metabolism of adrenal corticosteroids and hypertension: clues gut-cleansing antibiotics give us. Morris DJ; Brem AS Physiol Genomics; 2019 Mar; 51(3):83-89. PubMed ID: 30681907 [TBL] [Abstract][Full Text] [Related]
5. An alternative explanation of hypertension associated with 17α-hydroxylase deficiency syndrome. Morris DJ; Latif SA; Brem AS Steroids; 2014 Jan; 79():44-8. PubMed ID: 24176792 [TBL] [Abstract][Full Text] [Related]
6. Impact of dietary Na+ on glycyrrhetinic acid-like factors (kidney 11beta-(HSD2)-GALFs) in human essential hypertension. Morris DJ; Lo YH; Lichtfield WR; Williams GH Hypertension; 1998 Jan; 31(1 Pt 2):469-72. PubMed ID: 9453347 [TBL] [Abstract][Full Text] [Related]
7. Apparent mineralocorticoid excess syndrome: an overview. Palermo M; Quinkler M; Stewart PM Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):687-96. PubMed ID: 15761540 [TBL] [Abstract][Full Text] [Related]
8. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess. Whorwood CB; Stewart PM J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678 [TBL] [Abstract][Full Text] [Related]
9. [From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids]. Levtchenko EN; Deinum J; Knoers NV; Hermus AR; Monnens LA; Lenders JW Ned Tijdschr Geneeskd; 2007 Mar; 151(12):692-4. PubMed ID: 17447595 [TBL] [Abstract][Full Text] [Related]
10. In vitro methods to assess 11β-hydroxysteroid dehydrogenase type 2 activity. Kley M; Moser SO; Winter DV; Odermatt A Methods Enzymol; 2023; 689():167-200. PubMed ID: 37802570 [TBL] [Abstract][Full Text] [Related]
11. Correlation of glycyrrhetinic acid-like factors (kidney 11beta-HSD2-GALFs) with urinary free cortisol and plasma renin activity in essential hypertension. Morris DJ; Latif SA; Lo YH; Abrampah K; Brem AS; Lichtfield WR; Williams GH J Am Soc Hypertens; 2008; 2(4):286-93. PubMed ID: 20409908 [TBL] [Abstract][Full Text] [Related]
12. Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature. Adamidis A; Cantas-Orsdemir S; Tsirka A; Abbott MA; Visintainer P; Tonyushkina K Pediatr Endocrinol Rev; 2019 Mar; 16(3):335-358. PubMed ID: 30888125 [TBL] [Abstract][Full Text] [Related]
13. The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension. Ferrari P Biochim Biophys Acta; 2010 Dec; 1802(12):1178-87. PubMed ID: 19909806 [TBL] [Abstract][Full Text] [Related]
14. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322 [TBL] [Abstract][Full Text] [Related]
15. Why do humans have two glucocorticoids: A question of intestinal fortitude. Morris DJ Steroids; 2015 Oct; 102():32-8. PubMed ID: 26144050 [TBL] [Abstract][Full Text] [Related]
16. The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Fürstenberger C; Vuorinen A; Da Cunha T; Kratschmar DV; Saugy M; Schuster D; Odermatt A Toxicol Sci; 2012 Apr; 126(2):353-61. PubMed ID: 22273746 [TBL] [Abstract][Full Text] [Related]
17. 11Beta-hydroxylase deficiency and other syndromes of mineralocorticoid excess as a rare cause of endocrine hypertension. Melcescu E; Phillips J; Moll G; Subauste JS; Koch CA Horm Metab Res; 2012 Nov; 44(12):867-78. PubMed ID: 22932914 [TBL] [Abstract][Full Text] [Related]
18. Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function. Quinkler M; Zehnder D; Lepenies J; Petrelli MD; Moore JS; Hughes SV; Cockwell P; Hewison M; Stewart PM Eur J Endocrinol; 2005 Aug; 153(2):291-9. PubMed ID: 16061836 [TBL] [Abstract][Full Text] [Related]
20. Expression of 11β-hydroxysteroid dehydrogenase 1 and 2 in patients with chronic rhinosinusitis and their possible contribution to local glucocorticoid activation in sinus mucosa. Jun YJ; Park SJ; Kim TH; Lee SH; Lee KJ; Hwang SM; Lee SH J Allergy Clin Immunol; 2014 Oct; 134(4):926-934.e6. PubMed ID: 24810847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]